Boiron SA

BOI

Company Profile

  • Business description

    Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company’s products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.

  • Contact

    2, Avenue de l’Ouest Lyonnais No. 039
    Messimy69510
    FRA

    T: +33 478456100

    E: [email protected]

    http://www.boiron.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    2,771

Stocks News & Analysis

stocks

Sales shine but broader macro outlook darkens for this ASX share

US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks

Chart of the Week: US equity market trading at an attractive discount

The latest from our Chief US Market Strategist.
stocks

Undervalued ASX share retains wide moat rating despite regulatory pressures

Proposed price regulation impacts our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,168.9043.800.48%
CAC 408,203.2460.63-0.73%
DAX 4023,712.39368.24-1.53%
Dow JONES (US)47,867.3242.60-0.09%
FTSE 10010,586.4322.45-0.21%
HKSE25,752.40140.62-0.54%
NASDAQ22,571.0363.97-0.28%
Nikkei 22555,895.32413.10-0.73%
NZX 50 Index13,273.8119.870.15%
S&P 5006,774.438.38-0.12%
S&P/ASX 2008,973.2057.800.65%
SSE Composite Index3,966.1728.83-0.72%

Market Movers